[Targeting therapy in rheumatoid arthritis].
Sugita
Takahisa
T
t-sugita@tanabe.co.jp
D000818:Animals; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology*; D015195:Drug Design; D006801:Humans; D000069283:Rituximab; D015398:Signal Transduction / Q000502:physiology; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; D048051:p38 Mitogen-Activated Protein Kinases